Drugs / RO7616789
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05619744 | Jan 2023 → Mar 2025 | small cell lung carcinoma | Hoffmann-La Roche | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RO7616789 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05619744 ↗ |
| Route | Intravenous | “RO7616789 solution for infusion will be administered intravenously” NCT05619744 ↗ |